<DOC>
	<DOCNO>NCT02585700</DOCNO>
	<brief_summary>This phase I , double-blind , randomize , placebo-controlled trial two group participant receive seasonal trivalent split , inactivated influenza vaccine ( A/H1N1 ; A/H3N2 B ) placebo ( phosphate buffer saline ) . A total 60 healthy male female adult 18 45 year age randomize receive vaccine ( 30 ) placebo ( 30 ) .</brief_summary>
	<brief_title>A Study Seasonal Trivalent Split , Inactivated Influenza Vaccine</brief_title>
	<detailed_description>This phase 1 , double blind , randomize , placebo-controlled study . The study conduct 1 site Serbia . Sixty ( 60 ) healthy male female adult , 18 45 year age , enrol trial . Subjects randomize 1:1 one two treatment allocation : 30 vaccine , 30 placebo . The study utilize `` randomized block design '' assure balance 1:1 vaccine placebo subject enrol . The study double blind , mean study subject , investigator , sponsor unaware treatment allocate subject clinical trial database declare final lock . The study take 5 month complete , subject involve 3 month day injection . The justification 3 month follow , rather 6 month follow inactivate vaccine follow standard manufacturing practice standard antigen . The safety inactivate influenza vaccine well-established . Adding length follow result delay future test vaccine licensure .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male female adult 18 45 year age enrollment visit . Literate ( selfreport ) willing provide write informed consent . Healthy , establish medical history , physical examination , screen laboratory evaluation . Capable willing complete Memory Aids willing return followup visit . For female , willing utilize reliable birth control measure ( e.g. , intrauterine device , hormonal contraception , condom ) Day 0 Day 21 visit . Participation another clinical trial involve therapy within previous three month plan enrollment trial period study . Receipt nonstudy vaccine within 4 week prior enrollment refusal postpone receipt vaccine Day 21 visit . Current recent ( within 2 week vaccination ) acute illness without fever . Receipt immune globulin blood product within 3 month prior study enrollment plan receipt product prior Day 21 visit . Chronic administration ( define 14 consecutivelyprescribed day ) immunosuppressant immunemodulating therapy within six month prior study vaccination . ( For corticosteroid , mean prednisone equivalent , equal 0.5 mg per kg per day ; topical steroid allow . ) History asthma . Hypersensitivity previous administration vaccine . Suspected known hypersensitivity study vaccine component , include chicken egg protein . Acute chronic clinically significant pulmonary , cardiovascular , hepatobiliary , metabolic , neurologic , psychiatric renal functional abnormality , determine medical history , physical examination clinical laboratory screening test , opinion investigator , might interfere study objective . History blood solid organ cancer . History thrombocytopenic purpura know bleed disorder . History seizure . Known suspect immunosuppressed immunodeficient condition kind . Confirmed HBV HCV infection Known HIV infection ( selfreport ) . Known active tuberculosis symptom active tuberculosis , regardless cause ( selfreport ) . History chronic alcohol abuse and/or illegal drug use . Pregnancy lactation . ( A negative pregnancy test require administration study product woman childbearing potential . ) History GuillainBarr√© Syndrome Any condition , opinion investigator , would increase health risk subject he/she participates study would interfere evaluation study objective .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>